Skip to main content

Neutropenia News

Related terms: Agranulocytosis, Granulocytopenia, Granulopenia

FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen

PISCATAWAY, N.J.--(BUSINESS WIRE)-- March 2, 2022 Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for...

FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen

July 20, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen1...

FDA Approves Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018 /PRNewswire/ – Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food...

FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)

March 6, 2015 – The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States. Biological products are generally derived...

FDA Approves Tbo-filgrastim for Severe Neutropenia in Certain Cancer Patients

August 29, 2012 – The U.S. Food and Drug Administration today approved Sicor Biotech’s tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, ...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Neutropenia Associated with Chemotherapy